Shares of Royal Sense witnessed a sharp increase of 4.98% on the NSE, trading at ₹230.85 as of 9:33 AM on Thursday. The surge comes on the back of the company’s announcement of the launch of six new pharmaceutical products on November 21, 2024.
New Product Details:
- Cefix-O Tablets
- Cefix-CV Tablets
- Steropenam 1 gm Injection
- Ugmtin 1.2 gm Injection
- Ugmtin Syrup
- Nomoceft 1 gm Injection
Launch Highlights:
- Date of Launch: November 21, 2024
- Category: Pharmaceuticals
- Market: The products are targeted exclusively at the domestic market.
Investor Sentiment:
The launch highlights Royal Sense’s commitment to expanding its portfolio in the pharmaceutical space, which has been well-received by the market. The introduction of new products is expected to bolster the company’s revenue streams and enhance its position in the domestic pharmaceutical market.
